

**26-MAY-2017 18:11**  
**OPEN STUDIES IRB REPORT**

<u>Disease Site</u>	<u>Study</u>	<u>Study Name</u>	<u>Open Date</u>	<u>Number of Active Institutions</u>	<u>Number of Current IRBs</u>
BREAST	S1007	Breast,Adj,N1,Endocrine+/-Chemo	15-JAN-11	430	214
	S1207	Brst,Adj,Endocrine+/-Everolimus	03-SEP-13	482	246
	S1416	Brst, TNBC/BRCA, Cis+/- ABT-888	07-JUL-16	248	119
	S1418	Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	15-NOV-16	314	126
	A011106	Breast, Neoadj, ALTERNATE study	15-FEB-14	260	121
	A011203	Breast, Adv, Tam vs Endoxifen	27-JAN-15	240	90
	A011401	Breast, adj, Stage II/III HER2-, weight loss	29-AUG-16	246	126
	B55	Brst, Adj Olaparib for BRCA,TNBC	03-JUL-14	407	185
	E1Z11	Brst,Genetic Predictors of AIMSS	10-MAY-13	256	92
	E2112	Brst,Adv,Exemestane+/-Entinostat	02-JAN-14	297	163
	NRGBR003	Brst,Adj,TNBC,AC -> WP +/- Carbo	22-JAN-15	441	216
	Breast	A011502	Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	08-DEC-16	0
CCD	S1415CD	TrACER CSF Standing Order Intervention for FN	01-SEP-16	52	65
	S1417CD	Colorectal, Cost Cohort Study	13-MAY-16	207	56
	A011104	Preoperative Breast MRI	21-FEB-14	175	63
ERLYTX	S1609	Rare Tumor, Comb Nivo/Ipi	13-JAN-17	309	120
	A071102	GBM, adj TMZ +/- Veliparib	19-SEP-14	356	157
	A071401	Prog Meningiomas,SMO/AKT/NF2 Inhib	06-AUG-15	234	99
	ARST1321	NonRhabdo STS,Pazopanib (PAZNTIS)	16-MAY-14	220	113
	EAY131	MATCH	12-AUG-15	435	226
GI	S1505	Panc,Resect, Perioperative Chemo	12-OCT-15	291	134
	S1513	Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888	01-SEP-16	275	117
	A021501	Adeno Panc,Borderline Resect,Chemo vs ChemoRT	01-DEC-16	0	2
	E7208	CRC,Adv, Irino/Cet+/-Ramucirumab	20-FEB-14	199	86
	EA2133	Anal, local recur/met, Cis+5FU vs Taxol/Carbo	29-JAN-16	0	16
	EA2142	GI NEC, Adv G3, EP vs TMZ + CAP	06-NOV-15	182	68
	N1048	Rectal,LocalAdv,ChemoRT+/-FOLFOX	13-JAN-12	0	160
	NRGGI002	Rectal, Ph II, Sensitization using TNT	12-OCT-16	191	98
	R0848	Panc, Adj, Erlotinib v ChemoRT	01-MAR-14	0	148
	GU	S1216	Pros Adv, ADT +/- TAK-700 or Bic	01-MAR-13	143
S1314		Blad, COXEN Neoadj. Chemo + Cyst	11-JUL-14	232	112
S1500		pRCC,Adv, Sunitinib vs MET inhib	05-APR-16	191	82

**26-MAY-2017 18:11**  
**OPEN STUDIES IRB REPORT**

18:10 Friday, May 26, 2017 2

<u>Disease Site</u>	<u>Study</u>	<u>Study Name</u>	<u>Open Date</u>	<u>Number of Active Institutions</u>	<u>Number of Current IRBs</u>
	S1602	Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	07-FEB-17	74	37
	S1605	Blad, BCG-Unresponsive NMIBC, Atezolizumab	07-FEB-17	93	42
	A031102	GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	01-JUL-15	6	5
	E2810	Renal, Pazopanib vs Placebo	17-APR-12	173	83
	EA8141	UTUC, HG, Chemo then Surg	27-JAN-15	159	75
	R0924	Pros, NADT+WPRT vs. NADT+P&SV RT	07-JUL-11	0	153
LEUK	S1312	ALL, CD22+, REL/REF, Inotuzumab+CVP	01-APR-14	5	6
	S1318	ALL, Age 65+, Ph±, Blinatumomab	12-JAN-15	174	68
	S0919	Rel AML: Pravastatin+Ida+Ara-C	15-AUG-09	86	29
	E1910	BCR-ABL-neg, B ALL, Blinatumomab	23-DEC-13	157	80
	E2906	AML, Age 60+, Clo vs Dauno+Cy	24-FEB-11	157	81
	NHLBIMDS	LEUK, National MDS Study	05-APR-16	48	17
LUNG	S1400	SCCA,Adv, Biomarker Master	15-JUN-14	439	217
	S1400G	HRRD: Talazoparib (BMN 673)	07-FEB-17	431	207
	S1400I	Non-Match: Nivo + Ipi vs Nivo	18-DEC-15	439	216
	S1403	Adv,EGFR-mt,Afatinib+/-Cetuximab	25-MAR-15	223	87
	S1507	NSCLC, Adv, Kras Mut, Trametinib + Docetaxel	18-JUL-16	164	78
	8811	NSCLC, Stage III,ChemoRT+ABT-888	02-JAN-13	108	36
	A081105	ALCHEMIST1, EGFR mut, Erlotinib	02-JAN-14	0	246
	A151216	ALCHEMIST0 - screening	06-FEB-14	459	247
	C140503	NSCL, Lobect v Sublobar resect	09-JUL-07	104	56
	C30610	SCLC, Thoracic RT	21-MAR-08	240	111
	E4512	ALCHEMIST2, ALK mut, Crizotinib	18-AUG-14	463	244
	EA5142	ALCHEMIST3, Non-match, Nivolumab	16-MAY-16	433	224
	NRGCC003	SCLC, PCI or HA-PCI	07-DEC-15	318	128
	R1306	NSCLC,Adv,ALK/EGFR,TargetAgents	04-NOV-13	144	67
LYMPH	A051301	ABC DLBCL, Auto HCT and Ibrutinib/Placebo	15-JUL-16	104	43
MELAN	S1320	Adv, BRAF mut, Inter v Contin	22-JUL-14	242	100
	S1404	Melan, Adv, HD-IFN/Ipilimumab vs MK-3475	15-OCT-15	416	174
	S1512	Melan, Adv, Desmoplastic, MK-3475 (pembro)	20-OCT-16	49	20
	EA6134	Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	15-DEC-15	340	137
	EA6141	Melan, Avd, Nivolumab+Ipi ± Sargmostim	01-MAR-16	263	102
MMYEL	E1A11	MM, frontline, BLD vs CLD	22-NOV-13	299	125

**26-MAY-2017 18:11**  
**OPEN STUDIES IRB REPORT**

<u>Disease Site</u>	<u>Study</u>	<u>Study Name</u>	<u>Open Date</u>	<u>Number of Active Institutions</u>	<u>Number of Current IRBs</u>
	E3A06	AMM, Lenalidomide vs Observation	08-NOV-10	275	123
OTHER	A091202	Sarc, Efatutazone vs Placebo, Unresect ,Lipo	02-SEP-14	39	22
	A091304	Adv Sarc, MLN0128 v Pazopanib, PhI/II	26-JAN-15	176	65
	A091305	HN, Adv, Thyroid PPAR agonist + Chemo	01-SEP-14	90	28
	A091401	Sarc,	18-JUN-15	195	76
	A091404	HN, AR+, Enzalutamide	25-SEP-15	23	7
	AOST1521	Osteo CDX-011 in Rec/Ref Dz,Ph 2	02-JUL-15	76	44
	E3311	Oroph,Srg + Low or Std IMRT	01-MAR-14	175	65
	EAQ152	Communication & education in tumor profiling	26-SEP-16	165	76
	G0281	Ovar, Recur/prog LG, IC chemo vs trametinib	27-FEB-14	0	15
	NRGBN001	HN, novel vs. std chemoradiation + chemo	28-AUG-15	0	92
	NRGGY004	Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo	04-FEB-16	338	147
	NRGGY005	OVAR, Cedir vs Olaparib vs C+O vs Std of Care	06-FEB-16	123	50
	NRGHN001	Nasopharyngeal , Individual Tx EBV	21-APR-14	202	86
	NRGHN002	HN, Adv, Orophyx RT vs RT+ Chemo	27-OCT-14	284	102
	R0724	Cervical, Chem+RT +/- Adj. Chemo	15-JAN-14	232	95
	R0920	HN, Adv, Postop IMRT ± Cetuximab	24-DEC-13	384	182
	R1216	HN, Adv,Cis vs Dtx vs Dtx+Cetux	18-MAR-13	276	117
PREV	S0820	PACES: ColrecStg0-3 Blind DFMO/Sulindac	01-MAR-13	305	110
	A211102	Breast, Atypia via RPFNA, Metformin v Placebo	01-FEB-15	29	7
	A211201	Breast Density, MA.32 companion	22-AUG-12	54	13
SURV	S1316	Compar. Effectiv. Trial for MBO	09-MAR-15	10	16
	E1Q11	EROS: Reproductive Health in Cancer Survivors	30-SEP-15	0	35
SXQOL	A221101	Glioma, Nuvigil/Placebo Fatigue	03-JUN-13	184	80
	A221102	Brst,AI Arthralgia,Testosterone	07-SEP-12	0	67